- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05013801
A Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma
A Randomized, Controlled, Single Center Clinical Study to Evaluate the Effect of Facial Serum Q69 in Moderating the Appearance of Mild to Moderate Melasma
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a single blind (outcomes assessor), randomized, 2 cell, full face study to evaluate changes in mild malar melasma through use of a cosmetic facial serum formulation or marketed 2% hydroquinone. This study will accept up to fifty participants per cell (100 participants overall) who meet the inclusion/exclusion criteria to ensure that at least forty participants per cell complete the study. Participants will be randomized to receive either the cosmetic product or the hydroquinone product.
The study schedule will be different depending which product the subject is allocated to.
If accepted onto the study, all participants will be provided with a marketed face wash and moisturiser to use for one week before the baseline visit.
At the baseline visit, following collection of baseline measures subjects will be allocated to either the cosmetic product or 2% hydroquinone. Products will be applied only to lesional areas on the face twice daily. Participants will also be provided with a sunscreen for use throughout the test phase of the study. They will continue to use the face wash and moisturiser with which they have previously been provided.
Participants allocated to the cosmetic product will be asked to return to the study centre for assessments at weeks 4, 8, 12 and regression (8 weeks after stopping product application).
Participants allocated to 2% hydroquinone will be asked to return to the study centre 3 days, 1, 2, 4, 6 and 8 weeks after baseline and regression 8 weeks after stopping product application).
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Shanghai, China
- Shanghai Skin Disease Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant in general good health as per the Medical History screening criteria
- Female participants between 18-55 years of age at first study visit (both inclusive)
- Participant having mild to moderate facial melasma
- Participants having skin type II-IV
- Participants with melasma pigmentation which has been stable for 3 months (self-reported)
- Participants who are willing to dedicate time and follow the instructions as per the study protocol
- Participants willing to give a voluntary written informed consent for activities in the study for imaging and agree to come for regular study visits
Exclusion Criteria:
- Participants are pregnant or anticipating pregnancy during the study period or are currently breast-feeding as self-reported
- Participants with known allergies to facial skin care products including sunscreens, bar or liquid cleansing products, moisturizers/lotions, lightening/brightening products, antiaging products, adhesives, and/or fragrances
- Participants who are consistently exposed to sunlight either through their work or habits, such as continuous exposure to sunlight that is more than 2 hours of duration.
- Participants who have sunburn, suntan, scars, nevi, excessive hair, tattoos, birthmarks, or any other dermal conditions on the test sites that might influence the test results in the opinion of the Investigator
- Participant with dry or scaly facial skin or with self-perceived pimple prone &/or sensitive skin or with any other signs of significant local irritation
- Participants having a history or currently having skin conditions such as eczema or psoriasis, severe acne, nodules, cyst, eczema, seborrheic dermatitis, severe excoriations on the face currently or in adult life
- Participants allergic to sulphite containing drugs
- Participants who have used any medication (including Hydroquinone, retinoids) in the last two 2 months for melasma treatment
- Participants not tolerant to retinoids or Vitamin-A related medicines or products
- Participants with a history of Asthma, Hypertension, diabetes, or any other illness that the Investigator deems inappropriate for participation or could interfere with the study outcome
- Participants taking medication continuously/regularly every day such as corticosteroids or non-steroidal anti-inflammatories, topically for four weeks or orally for eight weeks prior to the study
- Participants who are currently participating in any clinical study
- Participants who have participated in any clinical trial involving the face in the past 8 weeks prior to inclusion into this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cosmetic Facial Serum Q69
Cosmetic facial serum.
To be used twice daily on lesional areas of the face for 12 weeks.
|
Cosmetic facial serum
|
Other: 2% Hydroquinone
2% hydroquinone cream to be used twice daily on lesional areas of the face as directed by the dermatologist for no longer than 8 weeks.
|
2% Hydroquinone cream
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in L*
Time Frame: 0 - 12 weeks + regression (8 weeks)
|
CIELAB colour space L* (perceptual lightness), measured using Konica Minolta CM-2600d portable spectrophotometer
|
0 - 12 weeks + regression (8 weeks)
|
Change in modified Melasma Area Severity Index (mMASI)
Time Frame: 0 - 12 weeks + regression (8 weeks)
|
Melasma severity on four facial areas (forehead, right malar region, left malar region and chin) is assessed based on three variables: percentage of the total area involved (A), darkness (D), and homogeneity (H). Area (A): a numerical value is assigned to % area involved as follows. 0=no involvement; 1=<10% ; 2=10-29%; 3=30-49%; 4=50-69%; 5=70-89%; and 6=90-100%. Darkness of melasma (D) is graded on a scale of 0 to 4: 0=normal skin color without evidence of hyperpigmentation; 1=barely visible hyperpigmentation; 2=mild hyperpigmentation; 3=moderate hyperpigmentation; 4=severe hyperpigmentation. Homogeneity of hyperpigmentation (H) is graded on a scale of 0 to 4 as follows: 0=normal skin color without evidence of hyperpigmentation; 1=specks; 2=small patchy areas <1.5 cm diameter; 3= >2 cm diameter; 4=uniform skin involvement without any clear areas. The sum of D and H is multiplied by A and by the percentages of the four facial areas (10-30%). Total score is 0-48. |
0 - 12 weeks + regression (8 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in evenness of skin tone
Time Frame: 0 - 12 weeks + regression (8 weeks)
|
Evenness of skin tone as assessed through analysis of images captured using the Canfield Scientific VISIA-CR imaging system
|
0 - 12 weeks + regression (8 weeks)
|
Change in visual skin glow
Time Frame: 0 - 12 weeks + regression (8 weeks)
|
Composite parameter calculated using output from CM2600d and VISIA-CR
|
0 - 12 weeks + regression (8 weeks)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in perception of melasma as assessed using MelasQOL
Time Frame: 0 - 12 weeks + regression (8 weeks)
|
Quality of life questionnaire specifically developed for use with melasma
|
0 - 12 weeks + regression (8 weeks)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Yimei Tan, MD, Shanghai Skin Disease Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SKN-SFF-3469
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melasma
-
Mesoestetic Pharma Group S.L.Completed
-
ConBio, a Cynosure CompanyCompleted
-
University of Nove de JulhoRecruiting
-
Jinnah Postgraduate Medical CentreActive, not recruiting
-
China Medical University HospitalCompleted
-
VIST - Faculty of Applied SciencesActive, not recruiting
-
China Medical University HospitalApollo Medical Optics, LtdCompleted
-
Combined Military Hospital AbbottabadCompleted
-
Northwestern UniversityCompleted
-
Centre Hospitalier Universitaire de NiceCompleted
Clinical Trials on Cosmetic facial serum Q69
-
Kyunghee UniversityUnknown
-
Johnson & Johnson Consumer Inc. (J&JCI)CompletedDermatitis, Atopic | Rosacea | Acne Vulgaris | Sensitive SkinUnited States
-
Amazentis SAproDERM GmbHCompleted
-
Integrative Skin Science and ResearchArbonneActive, not recruitingWrinkleUnited States
-
Integrative Skin Science and ResearchArbonneActive, not recruiting
-
Mayo ClinicCompletedSkin AgingUnited States
-
Revision SkincareStephens & Associates, Inc.CompletedWrinkle | Photoaging | Fine LinesUnited States